GlassScriptPhysician profile
John A Moorhead
NPI 1245289057
$524.52
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $15.63 · 2021: $18.96.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $109.36 | 2019 | |
| Amarin Pharma, INC. | $68.19 | 2019 | |
| Novo Nordisk INC | $64.71 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $61.44 | 2019 | |
| Pfizer INC. | $34.59 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.15 | 2019 | |
| Shire North American Group INC | $27.18 | 2019 | |
| Antares Pharma, INC. | $26.40 | 2019 | |
| Si-Bone, INC. | $20.39 | 2019 | |
| Lilly USA, LLC | $16.27 | 2019 | |
| Neuronetics, INC. | $14.56 | 2019 | |
| Pacira Therapeutics, INC. | $14.56 | 2019 | |
| Endo Pharmaceuticals INC. | $13.63 | 2019 | |
| Genentech USA, INC. | $12.18 | 2019 | |
| Sanofi Pasteur INC. | $11.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Moorhead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.